Although as of 2020, over 92 fusion partners have been discovered in ALK(+) NSCLC, in solid cancers, the most common ALK fusion partner is echinoderm microtubule-associated protein-like 4 (EML4), which was found in 6.7% of cases. Here, EML4 is linked to non-small cell lung carcinoma.